Top 5 Stocks to Buy Now
→ Solar is dead. Here’s what replaces it. (From Behind the Markets) (Ad)tc pixel
NASDAQ:IBIO

iBio Q1 2026 Earnings Report

iBio logo
$1.64 -0.02 (-0.91%)
As of 03:45 PM Eastern
This is a fair market value price provided by Massive. Learn more.
ProfileEarnings HistoryForecast

iBio EPS Results

Actual EPS
-$0.11
Consensus EPS
-$0.07
Beat/Miss
Missed by -$0.04
One Year Ago EPS
N/A

iBio Revenue Results

Actual Revenue
$0.10 million
Expected Revenue
N/A
Beat/Miss
N/A
YoY Revenue Growth
N/A

iBio Announcement Details

Quarter
Q1 2026
Date
11/12/2025
Time
After Market Closes
Conference Call Date
Wednesday, November 12, 2025
Conference Call Time
4:00PM ET

Upcoming Earnings

iBio's Q4 2026 earnings is estimated for Friday, September 4, 2026, based on past reporting schedules

Conference Call Resources

Powered by Quartr

Earnings Documents

iBio's Q1 2026 Earnings ReleaseEarnings Release
(8-K)
iBio's Q1 2026 Quarterly ReportQuarterly Report
(10-Q)

iBio Earnings Headlines

iBio, Inc. (NASDAQ:IBIO) Receives Average Recommendation of "Buy" from Analysts
June 20, 2026  |  americanbankingnews.comhttps://www.americanbankingnews.com/?p=30850732
Could iBio (IBIO) Be an Underrated Obesity Stock?
June 11, 2026  |  insidermonkey.comhttps://www.insidermonkey.com/blog/could-ibio-ibio-be-an-underrated-obesity-stock-1780088/
A drilling crew just broke a record nobody expected
A drilling crew in Beaver County, Utah hit 15,765 feet of solid granite in 16 days - a job the Department of Energy projected would take 64. They reached DOE's 2035 performance targets twelve years early, cutting costs in half within 18 months. When Congress moved to cut solar and wind tax credits, this energy source kept its full credits through 2033. One company has been building in this space for sixty years, and a July 4th catalyst is now 12 days away.tc pixel
June 24 at 1:00 AM  |  Behind the Markets (Ad)
5 Under-the-Radar AI Stocks to Buy in 2026
June 11, 2026  |  insidermonkey.comhttps://www.insidermonkey.com/blog/5-under-the-radar-ai-stocks-to-buy-in-2026-1778220/
iBio to Participate in Upcoming Healthcare Investor Conferences
June 2, 2026  |  globenewswire.comhttps://www.globenewswire.com/news-release/2026/06/02/3305569/0/en/ibio-to-participate-in-upcoming-healthcare-investor-conferences.html
iBio, Inc.: iBio Becomes a Clinical-Stage Company with First Participant Dosed in Phase 1 Clinical Trial of IBIO-600 in Adults with Obesity
June 2, 2026  |  finanznachrichten.dehttps://www.finanznachrichten.de/nachrichten-2026-06/68657523-ibio-inc-ibio-becomes-a-clinical-stage-company-with-first-participant-dosed-in-phase-1-clinical-trial-of-ibio-600-in-adults-with-obesity-399.htm
See More iBio Headlines
Get Earnings Announcements in your inbox

Want to stay updated on the latest earnings announcements and upcoming reports for companies like iBio? Sign up for Earnings360's daily newsletter to receive timely earnings updates on iBio and other key companies, straight to your email.

About iBio

iBio (NASDAQ:IBIO), a biotechnology company, provides contract development and manufacturing services to collaborators and third-party customers in the United States. The company operates in two segments: Biopharmaceuticals and Bioprocessing. Its lead therapeutic candidate is IBIO-100 that is being advanced for investigational new drug development for the treatment of systemic scleroderma and idiopathic pulmonary fibrosis. The company is also developing vaccine candidates comprising IBIO-200 and IBIO-201, which are in preclinical development for the prevention of severe acute respiratory syndrome coronavirus 2; and IBIO-400 for the treatment of classical swine fever. In addition, it is developing recombinant proteins for third parties on a catalog and custom basis; and offers a range of process development, manufacturing, filling and finishing, and bio analytic services. iBio, Inc. has a license agreement with Planet Biotechnology, Inc. to develop therapeutics for infectious diseases; collaboration agreement with The Texas A&M University System for the development of coronavirus disease 2019 vaccine candidates; license agreement with the University of Natural Resources and Life Sciences, Vienna; and collaboration agreement with CC-Pharming Ltd. The company is headquartered in Bryan, Texas.

View iBio Profile
Earnings Tools